Consumer Research2020-11-05T23:41:25-08:00

Consumer Research

  • Cannabis

Comprehensive Cannabis Pangenome

LOS ANGELES- A collaborative study led by the Salk Institute for Biological Studies has constructed the most comprehensive genetic map of Cannabis sativa to date, analyzing 193 genomes from 144 biological samples. This pangenome reveals ...

Cannabis in Psychedelic Therapy: Potential and Precautions

LOS ANGELES- The integration of cannabis into psychedelic-assisted psychotherapy is gaining attention as a potential treatment for various mental health conditions, including post-traumatic stress disorder (PTSD), depression, and anxiety. This approach involves administering cannabis in ...

Cybin Partners with Thermo Fisher for U.S. Manufacturing

LOS ANGELES- Cybin Inc. a neuropsychiatry company, has announced a collaboration with Thermo Fisher Scientific to support the Phase 3 clinical supply and potential commercial manufacturing of CYB003, its proprietary deuterated psilocin analog, for the ...

Rubicon Organics Appoints Glen Ibbott as Interim CFO

LOS ANGELES- Rubicon Organics Inc.  a Canadian producer of certified organic cannabis products, has appointed Glen Ibbott as Interim Chief Financial Officer, effective May 15, 2025. This leadership change follows the departure of Janis Risbin ...

Cresco Labs Reschedules Q1 2025 Earnings

LOS ANGELES- Cresco Labs Inc. has announced an updated schedule for its first quarter 2025 financial disclosures. The company will file its interim financial statements and Management’s Discussion and Analysis (MD&A) on Friday, May 30, ...

Medical Cannabis: Growth and Investment in 2024

LOS ANGELES- The medical cannabis industry is navigating 2024 with key players like Grow Group and Somai Pharmaceuticals leveraging new regulations and market dynamics to achieve ambitious growth targets. This article examines the recent developments ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands (NYSE: STZ), maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal ...

Critics Slam Thai Government’s Approach to Cannabis

LOS ANGELES- Critics have strongly opposed the Thai government's plan to reclassify cannabis as a narcotic, arguing that it will harm businesses involved in cannabis-based products and undermine investor confidence in the country. On July ...

Constellation Brands: Analysts Maintain Ratings

LOS ANGELES- On Monday, Argus reaffirmed its Buy rating on shares of Constellation Brands,  maintaining a price target of $306.00. Argus notes the stock's value, currently trading at 18 times the firm's fiscal year 2025 ...

Subscribe To Our Newsletter

Go to Top